Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O. Lenz HJ, et al. Among authors: innocenti f. J Clin Oncol. 2019 Aug 1;37(22):1876-1885. doi: 10.1200/JCO.18.02258. Epub 2019 May 1. J Clin Oncol. 2019. PMID: 31042420 Free PMC article. Clinical Trial.
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G. Cecchin E, et al. Among authors: innocenti f. J Clin Oncol. 2009 May 20;27(15):2457-65. doi: 10.1200/JCO.2008.19.0314. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364970
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F. Toffoli G, et al. Among authors: innocenti f. J Clin Oncol. 2010 Feb 10;28(5):866-71. doi: 10.1200/JCO.2009.23.6125. Epub 2009 Dec 28. J Clin Oncol. 2010. PMID: 20038727 Free PMC article. Clinical Trial.
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Kindler HL, et al. Among authors: innocenti f. J Clin Oncol. 2010 Aug 1;28(22):3617-22. doi: 10.1200/JCO.2010.28.1386. Epub 2010 Jul 6. J Clin Oncol. 2010. PMID: 20606091 Free PMC article. Clinical Trial.
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ. Innocenti F, et al. Clin Cancer Res. 2012 Jan 15;18(2):577-84. doi: 10.1158/1078-0432.CCR-11-1387. Epub 2011 Dec 5. Clin Cancer Res. 2012. PMID: 22142827 Free PMC article.
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, Innocenti F, Venook AP; Alliance for Clinical Trials in Oncology. Van Loon K, et al. Among authors: innocenti f. J Natl Cancer Inst. 2014 Aug 6;106(8):dju185. doi: 10.1093/jnci/dju185. Print 2014 Aug. J Natl Cancer Inst. 2014. PMID: 25099612 Free PMC article.
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Dickler MN, et al. Among authors: innocenti f. J Clin Oncol. 2016 Aug 1;34(22):2602-9. doi: 10.1200/JCO.2015.66.1595. Epub 2016 May 2. J Clin Oncol. 2016. PMID: 27138575 Free PMC article. Clinical Trial.
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F. Niedzwiecki D, et al. Among authors: innocenti f. J Clin Oncol. 2016 Sep 1;34(25):3047-53. doi: 10.1200/JCO.2015.65.4699. Epub 2016 Jul 18. J Clin Oncol. 2016. PMID: 27432924 Free PMC article.
Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB; Alliance for Clinical Trials in Oncology. Hatch AJ, et al. Among authors: innocenti f. Cancer Med. 2016 Sep;5(9):2249-60. doi: 10.1002/cam4.806. Epub 2016 Jul 27. Cancer Med. 2016. PMID: 27465221 Free PMC article.
429 results